SMAD4 and pancreatic ductal adenocarcinoma: Mutation or inactivation of SMAD4 promotes tumor metastasis, recurrence, or drug resistance, including in colorectal cancer (10), pancreatic ductal carcinoma (11), and lung cancer (12).